Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ZVZevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA)

NASDAQ Global Select · Currency in USD
$9.81 ▼ -0.52 (-5.03%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.50 ▲ +0.69 (+7.03%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$10.33
Open
$10.25
Day's Range
$9.76 – $10.25
52 Week Range
$8.01 – $15.04
Volume
977,652
Avg. Volume
1,133,780
Market Cap
$582.55M
Beta (5Y Monthly)
0.98
PE Ratio (TTM)
10.22
EPS (TTM)
$0.98
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.75

Profile: Zevra Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
61
CEO
Neil F. McFarlane
Website
zevra.com

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH).

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate $0.14 · Revenue est. $37.08M
DateEst.Actual
Aug 5, 2026$0.11$0.14Beat
May 6, 2026$0.06$0.60Beat
Mar 9, 2026$0.05$0.21Beat
Nov 5, 2025-$0.02-$0.01Beat
Aug 12, 2025$2.19$1.21Miss
May 13, 2025-$0.21-$0.06Beat

Analyst view

Consensus price target
$25.75 ▲ +162.5%
Range $20.00 – $35.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ZVRA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.